Read by QxMD icon Read

gleason grades

Xinyi Chen, Bin Ding, Ping Zhang, Shaoqing Geng, Jing Xu, Bo Han
Intraductal carcinoma of the prostate (IDC-P) is a malignant, clonal proliferation of cells growing within the basement membrane-bound structures of the prostate. IDC-P is usually associated with unfavorable clinicopathologic parameters such as large tumor volume, high-grade Gleason score, extra prostatic extension and seminal vesicle invasion. Majority of laboratory and patient data suggest that IDC-P represents intraductal spread of invasive carcinoma, rather than a precursor lesion. Additionally, relationship of IDC-P and adjacent invasive carcinoma has been investigated in a series of molecular studies...
March 6, 2018: Pathology, Research and Practice
Sami-Ramzi Leyh-Bannurah, Dominique Trudel, Mathieu Latour, Emanuele Zaffuto, Andree-Anne Grosset, Christine Tam, Veronique Ouellet, Markus Graefen, Lars Budäus, Armen G Aprikian, Louis Lacombe, Neil E Fleshner, Martin E Gleave, Anne-Marie Mes-Masson, Fred Saad, Pierre I Karakiewicz
To test the agreement between high-grade PCa at RP and TMA, and the ability of TMA to predict BCR. Validation of concordance between tissue microarray (TMA) and radical prostatectomy (RP) high-grade prostate cancer (PCa) is crucial because latter determines the treated natural history of PCa. We hypothesized that TMA Gleason score is in agreement with RP pathology and capable of accurately predicting biochemical recurrence (BCR). Data were provided from a multi-institutional Canadian sample of 1333 TMA and RP specimens with complete clinicopathological data...
April 6, 2018: Pathology Oncology Research: POR
Elizabeth C Bertsch, Cristina Magi-Galluzzi, Liang Cheng, Adeboye O Osunkoya
Recent studies have demonstrated that most patients with mucinous prostatic adenocarcinoma may have a better prognosis than those with conventional prostatic adenocarcinoma; however, the mechanism remains unclear. Loss of phosphatase and tensin homolog (PTEN) expression is known to occur in aggressive high-grade prostatic adenocarcinoma, but expression in mucinous prostatic adenocarcinoma has not been well characterized. In this study, we sought to analyze PTEN expression in mucinous prostatic adenocarcinoma, prostatic adenocarcinoma with mucinous features, and the adjacent conventional prostatic adenocarcinoma...
April 2018: Applied Immunohistochemistry & Molecular Morphology: AIMM
Cheng Wei, Chunhui Li, Magdalena Szewczyk-Bieda, Dilip Upreti, Stephen Lang, Zhihong Huang, Ghulam Nabi
OBJECTIVE: To test the diagnostic accuracy of SWE for the detection and phenotypic characterisation of PCa compared with whole-mount radical prostatectomy histopathology. MATERIALS AND METHODS: This was a prospective protocol-driven diagnostic accuracy study. 212 consecutive men undergoing laparoscopic radical prostatectomy (LRP) for clinically localised PCa were recruited into the study. Quantitative stiffness data of the prostate gland was obtained in each patient using an endocavitary transrectal transducer before LRP and compared with detailed histopathological examination of radical prostatectomy specimen using 3-D printing mold based technology ensuring improved image-histology orientation...
March 29, 2018: Journal of Urology
Amy Moore, Wen-Yi Huang, Kim Danforth, Roni Falk, Allison Meade, Rachel Bagni, Sonja I Berndt
BACKGROUND: Sexually transmitted infections and chronic inflammation have been associated with an increased risk of prostate cancer. Inflammatory mediators, such as cytokines and free radicals, have been hypothesized to play a role. METHODS: To explore the role of inflammation in prostate cancer risk further, we examined the association between pre-diagnostic serum levels of interleukin-16 (IL-16), an important pleiotropic cytokine, and prostate cancer risk among 932 Caucasian cases and 942 controls and 154 African-American cases and 302 controls in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial...
March 28, 2018: Cancer Causes & Control: CCC
Charlotte F Kweldam, Theodorus van der Kwast, Geert J van Leenders
The management of newly diagnosed prostate cancer is challenging because of its heterogeneity in histology, genetics and clinical outcome. The clinical outcome of patients with Gleason score 7 prostate cancer varies greatly. Improving risk assessment in this group is of particular interest, as Gleason score 7 prostate cancer on biopsy is an important clinical threshold for active treatment. Architecturally, four Gleason grade 4 growth patterns are recognized: ill-formed, fused, glomeruloid and cribriform. The aim of this review is to describe the role of cribriform growth in prostate cancer with respect to diagnosis, prognosis and molecular pathology...
February 2018: Translational Andrology and Urology
Melissa A Babcook, Mahmut Akgul, Seunghee Margevicius, Gregory T MacLennan, Pingfu Fu, Robert Abouassaly, Sanjay Gupta
BACKGROUND: We previously demonstrated that adenosine monophosphate-activated protein kinase (AMPKα) activity is significantly inhibited by Ser-486/491 phosphorylation in cell culture and in vivo models of metastatic and castration-resistant prostate cancer, and hypothesized these findings may translate to clinical specimens. METHODS: In this retrospective, single-institution pilot study, 45 metastatic prostate cancer cases were identified within the University Hospitals Cleveland Medical Center Pathology Archive with both metastasis and matched primary prostate tumor specimens in formalin-fixed, paraffin-embedded blocks, and complete electronic medical records...
March 26, 2018: Prostate
Nobuyoshi Takeuchi, Shinichi Sakamoto, Akira Nishiyama, Takuro Horikoshi, Yasutaka Yamada, Junpei Iizuka, Maihulan Maimaiti, Yusuke Imamura, Koji Kawamura, Takashi Imamoto, Akira Komiya, Yuzuru Ikehara, Koichiro Akakura, Tomohiko Ichikawa
BACKGROUND: We retrospectively assessed the clinical significance of the Prostate Imaging Reporting and Data System (PI-RADS), version 2, criteria based on biparametric magnetic resonance imaging (bp-MRI), together with the International Society of Urological Pathology (ISUP) grade, for predicting biochemical recurrence (BCR) after radical prostatectomy. MATERIALS AND METHODS: The data from 126 patients who had undergone radical prostatectomy were retrospectively analyzed...
February 24, 2018: Clinical Genitourinary Cancer
Tairo Kashihara, Satoshi Nakamura, Akihisa Wakita, Hiroyuki Okamoto, Koji Inaba, Rei Umezawa, Satoshi Shima, Keisuke Tsuchida, Kazuma Kobayashi, Kana Takahashi, Naoya Murakami, Yoshinori Ito, Hiroshi Igaki, Hiroyuki Fujimoto, Takashi Uno, Jun Itami
The aim of this study was to examine long-term outcomes in patients who received salvage radiotherapy (SRT) for biochemical recurrence (BRec) of prostate cancer after radical prostatectomy (RP). One hundred and twenty patients with prostate cancer who underwent SRT for BRec after RP without evidence of clinical disease were identified in our institution from 2002 to 2014. Prescription doses to prostate beds were 64.8 Gy with a fractional dose of 1.8 Gy in 96.7% of the patients. In three-dimensional conformal radiation therapy (3D-CRT), the seminal vesicle bed (SVB) was not included in the radiation fields...
March 23, 2018: Cancer Medicine
V Murthy, M Gupta, G Mulye, S Maulik, M Munshi, R Krishnatry, R Phurailatpam, R Mhatre, G Prakash, G Bakshi
AIMS: Stereotactic body radiotherapy (SBRT) in low- and intermediate-risk prostate cancer has shown encouraging results. However, its use in high-risk patients is limited due to lack of data regarding adequate radiotherapy dose, need for pelvic nodal treatment and androgen deprivation therapy. Herein we report our experience of SBRT in this subgroup. MATERIALS AND METHODS: Analysis of a prospectively maintained database of 68 consecutive patients of the National Comprehensive Cancer Network (NCCN) high-risk, very high-risk and node-positive adenocarcinoma prostate treated with SBRT was undertaken...
March 20, 2018: Clinical Oncology: a Journal of the Royal College of Radiologists
Andreas Maxeiner, Beatrice Kittner, Carsten Stephan, Thomas Fischer, Patrick Asbach, Matthias Haas, Tobias Penzkofer, Florian Fuller, Kurt Miller, Hannes Cash
OBJECTIVE: To examine the performance of a primary MRI/ultrasound fusion guided targeted biopsy (TB) and in combination with an added systematic biopsy (SB). PATIENTS AND METHODS: Analysis of 318 consecutive biopsy naïve men with suspicious mpMRI (PI-RADS score ≥3) undergoing transrectal TB and 10-core systematic biopsy (SB) between January 2012 and December 2016. The indication for performing a mpMRI was based on clinical parameters and decided by the treating urologist prior to admittance...
March 22, 2018: BJU International
Arvind Kumar, Deepa Hatwal, Neha Batra, Nidhi Verma
Background: Non-metastatic nm23H1 gene is thought to play a critical role in cell proliferation. Studies of nm23H1 have been done in many other malignancies. But none of these studies took up nm23H1 gene as predictor in the metastases of prostatic carcinoma. Aims and Objectives: To study the expression of nm23H1 in prostatic lesion and to correlate nm23H1 expression with presence of metastases, tumour stage, tumour grade and with PSA level serum. Setting and Design: Tertiary hospital based retrospective and prospective study done in a period of one year from thirty patients having prostatic lesion confirmed by biopsy...
January 2018: Indian Journal of Pathology & Microbiology
Teemu J Murtola, Ville Jy Vihervuori, Jorma Lahtela, Kirsi Talala, Kimmo Taari, Teuvo Lj Tammela, Anssi Auvinen
BACKGROUND: Diabetic men have lowered overall risk of prostate cancer (PCa), but the role of hyperglycaemia is unclear. In this cohort study, we estimated PCa risk among men with diabetic fasting blood glucose level. METHODS: Participants of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) were linked to laboratory database for information on glucose measurements since 1978. The data were available for 17,860 men. Based on the average yearly level, the men were categorised as normoglycaemic, prediabetic, or diabetic...
March 22, 2018: British Journal of Cancer
Zipei Cao, Lijuan Wei, Weizhi Zhu, Xuping Yao
BACKGROUND: Reduction of cyclin-dependent kinase inhibitor 2A (CDKN2A) (p16 and p14) expression through DNA methylation has been reported in prostate cancer (PCa). This meta-analysis was conducted to assess the difference of p16 and p14 methylation between PCa and different histological types of nonmalignant controls and the correlation of p16 or p14 methylation with clinicopathological features of PCa. METHODS: According to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement criteria, articles were searched in PubMed, Embase, EBSCO, Wanfang, and CNKI databases...
March 2018: Medicine (Baltimore)
Salvina Barra, Liliana Belgioia, Michela Marcenaro, Serena Callegari, Alice Pastorino, Luca Trapani, Francesca Cavagnetto, Stefania Garelli, Renzo Corvò
Background: After radical prostatectomy (RP) radiotherapy (RT) plays a role, both as adjuvant or salvage treatment. If negative features are present such as extracapsular extension, seminal vesicle invasion, lymph invasion, and positive surgical margins, RT after RP reduces the risk of recurrence, although it is associated with an increased risk of acute and late toxicities. An intensified RT delivered in a shortened time could improve clinical outcome and be safely combined with hormonal therapy (HT)...
2018: Cancer Management and Research
Lynn Tan, Luke L Wang, Weranja Ranasinghe, Raj Persad, Damien Bolton, Nathan Lawrentschuk, Shomik Sengupta
Background: The aim of the paper is to investigate the outcomes of patients younger than 55 years in Victoria, Australia undergoing radical prostatectomy (RP) for prostate cancer. Materials and methods: Data on all men undergoing RP in Victoria between January 1, 2004 and December 31, 2014 were obtained from the Victorian Cancer Registry. Tumor characteristics including Gleason grade, stage of disease (based on final pathology specimen), and cause of death were also obtained...
March 2018: Prostate International
Tian-Bao Huang, Guang-Chen Zhou, Chuan-Peng Dong, Li-Ping Wang, Yang Luan, Jing-Ting Ye, Xiao Gu, Xu-Dong Yao, Jun-Hua Zheng, Xue-Fei Ding
Marital status is an independent prognostic factor for survival in several types of cancer, but has not been fully studied in prostate cancer (PCa). A total of 95,846 men diagnosed with PCa were treated with radical prostatectomy (RP) between 2004 and 2009 within 18 Surveillance, Epidemiology and End Results registries. Survival curves were generated using Kaplan-Meier estimates and differences in survival were assessed using the log-rank test. Cox regression models were used to assess the impact of marital status on survival outcomes...
April 2018: Oncology Letters
Jennifer B Gordetsky, Luciana Schultz, Kristin K Porter, Jeffrey W Nix, John V Thomas, Maria Del Carmen Rodriguez Pena, Soroush Rais-Bahrami
MR/ultrasound fusion targeted biopsy(TB) routinely samples multiple cores from each MR lesion of interest. Pathologists can evaluate the extent of cancer involvement and grade using an individual-core(IC) or aggregate(AG) method, which could potentially lead to differences in reporting. We reviewed patients who underwent TB followed by radical prostatectomy(RP). TB cores were evaluated for grade and tumor extent by two methods. IC method: grade for each TB lesion was based on the core with the highest Gleason score...
March 15, 2018: Human Pathology
Anna Wallerstedt, Peter Strom, Henrik Gronberg, Tobias Nordstrom, Martin Eklund
Background: Studies have shown that 5α-reductase inhibitors (5-ARIs) decrease the risk for low-grade prostate cancer (PC), but results are conflicting concerning high-grade PCs. The objective of the present study is to evaluate the association between 5-ARI treatment for lower urinary tract symptoms and the risk for PC. Methods: This is a population-based prospective study on all men age 40 years and older with at least one prostate-specific antigen (PSA) test in Stockholm County from January 2007 until December 2015...
March 14, 2018: Journal of the National Cancer Institute
Jeff M Michalski, Jennifer Moughan, James Purdy, Walter Bosch, Deborah W Bruner, Jean-Paul Bahary, Harold Lau, Marie Duclos, Matthew Parliament, Gerard Morton, Daniel Hamstra, Michael Seider, Michael I Lock, Malti Patel, Hiram Gay, Eric Vigneault, Kathryn Winter, Howard Sandler
Importance: Optimizing radiation therapy techniques for localized prostate cancer can affect patient outcomes. Dose escalation improves biochemical control, but no prior trials were powered to detect overall survival (OS) differences. Objective: To determine whether radiation dose escalation to 79.2 Gy compared with 70.2 Gy would improve OS and other outcomes in prostate cancer. Design, Setting, and Participants: The NRG Oncology/RTOG 0126 randomized clinical trial randomized 1532 patients from 104 North American Radiation Therapy Oncology Group institutions March 2002 through August 2008...
March 15, 2018: JAMA Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"